National Institute of Mental Health; Notice of Closed Meetings, 3062 [2020-00688]
Download as PDF
<![CDATA[
3062
Federal Register / Vol. 85, No. 12 / Friday, January 17, 2020 / Notices
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Average
burden per
response
(in hours)
Total burden
hours
Form name
Application Waiver/Supplemental A Research ....................
Application Waiver/Supplemental B Clinical Care ..............
HHS 426 ........
HHS 426 ........
45
35
1
1
10
10
450
350
Total ..............................................................................
........................
........................
........................
........................
800
Terry Clark,
Office of the Secretary, Asst Paperwork
Reduction Act Reports Clearance Officer.
[FR Doc. 2020–00717 Filed 1–16–20; 8:45 am]
BILLING CODE 4150–38–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
lotter on DSKBCFDHB2PROD with NOTICES
Number of
responses per
respondent
Number of
respondents
Type of respondent
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; Early
Phase Clinical Trials for Psychosocial
Interventions.
Date: February 11, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: David I. Sommers, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
6001 Executive Blvd., Room 6154, MSC 9606,
Bethesda, MD 20892, 301–443–7861,
dsommers@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; Early
Phase Clinical Trials—Pharma/Device.
Date: February 20, 2020.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
VerDate Sep<11>2014
18:20 Jan 16, 2020
Jkt 250001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: David I. Sommers, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
6001 Executive Blvd., Room 6154, MSC 9606,
Bethesda, MD 20892, 301–443–7861,
dsommers@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Technology Transfer and Patent
Specialist, Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Suite 6D,
MSC9804, Rockville, MD 20852–9804;
Telephone: (301) 496–2644; Facsimile:
(240) 627–3117; Email: prabhuyo@
niaid.nih.gov.
SUPPLEMENTARY INFORMATION:
Dated: January 13, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
Intellectual Property
• U.S. Patent 9,481,866—issued
November 1, 2016, entitled ‘‘Methods
of Producing T Cell Populations
Enriched for Stable Regulatory TCells’’ [HHS Reference No. E–279–
2011/0–US–02]
• U.S. Divisional Application No.15/
284,840—filed October 4, 2016,
entitled ‘‘Methods of Producing T Cell
Populations Enriched for Stable
Regulatory T-Cells’. [HHS Reference
No. E–279–2011/0–US–03]
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory will be the United States and
the field of use will be limited to:
‘‘Human cell-based therapeutics for the
treatment of Hemophilia A in patients
that have inhibitory Factor VIII
antibodies.’’
The technology is directed to a
method for producing or growing cell
populations that are enriched for stable,
highly suppressive regulatory T cells
(Tregs). Tregs are critical in regulating
immune system processes that maintain
tolerance to self-antigens and prevent
immune mediated diseases. The method
takes a population of cells comprising
stable, regulatory T cells and enriched
for specific CD markers, cultures these
cells in the presence of interleukin-2, an
anti-CD3 antibody, an anti-CD28
antibody, and oligodeoxynucleotides of
specified length having a
phosphorothioate backbone, and yields
the expansion of the initial population
of regulatory T-cells. The expanded
Tregs may then be used for the
treatment of immune-mediated diseases.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
[FR Doc. 2020–00688 Filed 1–16–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Development of Regulatory
T-Cell Therapies for the Treatment of
Hemophilia A (HA)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the SUPPLEMENTARY INFORMATION
section of this notice to TeraImmune,
Inc. (‘‘TeraImmune’’) located in
Rockville, Maryland.
DATES: Only written comments and/or
applications for a license which are
received by the National Institute of
Allergy and Infectious Diseases’
Technology Transfer and Intellectual
Property Office on or before February 3,
2020 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Dr. Yogikala Prabhu,
SUMMARY:
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
E:\FR\FM\17JAN1.SGM
17JAN1
]]>Agencies
[Federal Register Volume 85, Number 12 (Friday, January 17, 2020)]
[Notices]
[Page 3062]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-00688]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; Early Phase Clinical Trials for Psychosocial
Interventions.
Date: February 11, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: David I. Sommers, Ph.D., Scientific Review
Officer, Division of Extramural Activities, National Institute of
Mental Health, National Institutes of Health, 6001 Executive Blvd.,
Room 6154, MSC 9606, Bethesda, MD 20892, 301-443-7861,
[email protected].
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; Early Phase Clinical Trials--Pharma/Device.
Date: February 20, 2020.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: David I. Sommers, Ph.D., Scientific Review
Officer, Division of Extramural Activities, National Institute of
Mental Health, National Institutes of Health, 6001 Executive Blvd.,
Room 6154, MSC 9606, Bethesda, MD 20892, 301-443-7861,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.242,
Mental Health Research Grants, National Institutes of Health, HHS)
Dated: January 13, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-00688 Filed 1-16-20; 8:45 am]
BILLING CODE 4140-01-P
